Chundeva Snezhana is a Full Professor at the Faculty of Electrical Engineering and Information Technologies (FEIT), Ss. Cyril and Methodius University in Skopje. She holds a Doctorate in Technical Sciences (2002) and has extensive experience in electrical engineering, including roles as an Assistant (1995-2003), Assistant Professor (2003-2008), and Associate Professor (2008-2013) before becoming a Full Professor in 2013. Her work focuses on transformers, power quality, renewable energy integration, and electromagnetic phenomena. She has contributed to international collaborations like the CIGRE/CIRED/UIE Joint Working Group C4.110, addressing voltage dip immunity and grid standards. Her research spans transformer design, smart grid technologies, and wind power integration, with over 50 publications in journals and conferences. She actively participates in academic and industry events, emphasizing practical applications of electrical engineering principles. Education: PhD in Technical Sciences (2002), MSc in Electrical Engineering (1994), BSc in Electrical Engineering (1991) from the University of Skopje. Research Interests: Electromagnetic analysis, transformer optimization, power quality, renewable energy systems, and smart grid technologies. Key Projects: Design optimization of special transformers, harmonic emission studies in wind parks, and hosting capacity analysis for microgenerators. Her work bridges theoretical and applied electrical engineering, with a focus on solving real-world challenges in energy systems and grid reliability. She has co-authored influential papers on transformer models, voltage dip immunity, and the integration of renewable energy sources into modern grids.
جستوجوی استاد و پژوهشگر
استاد راهنما، استاد دانشگاه یا پژوهشگر مناسب برای مسیر پژوهشیتان را پیدا کنید و با او ارتباط بگیرید.
نمایش ۷۲۱-۷۳۵ از ۳٬۵۸۹ استاد راهنما
اطلاعات این پروفایلها از صفحات عمومی دانشگاهها جمعآوری شده و ممکن است بهروز نباشد.
Professor Yonglun Luo is a leading academic at Aarhus University, affiliated with DANDRITE and the Department of Biomedicine. His research focuses on genome editing technologies (e.g., CRISPR), regenerative medicine, and translational applications such as xenotransplantation. Key projects include developing safer pig models for organ transplantation and studying extrachromosomal circular DNA (eccDNA) in cancer progression. He leads a multidisciplinary group applying cutting-edge tools like single-cell RNA/ATAC sequencing and machine learning. Research interests span biomarker discovery, CRISPR tool optimization, and ethical frameworks for gene therapy. He collaborates internationally on initiatives like the FarmGTEx consortium and the EU COST Action on genome editing. Teaching responsibilities include advanced courses in genome engineering for PhD students and personalized medicine for medical trainees. Current projects include EXOCURE (CRISPR-based muscle stem cell therapy for Duchenne muscular dystrophy) and CIRCULAR VISION (eccDNA dynamics modeling). His lab's innovations include TRAP-seq for CRISPR off-target analysis and pig cell landscape mapping for xenotransplantation compatibility.
- Molecular Biology
- Microbiology
- Food Hygiene
- +۵ مورد دیگر
Prof. Dr. Muhsin Aydın is a Professor at the Department of Biology, Faculty of Arts and Sciences, Adiyaman University. He holds a PhD in Molecular Biology from Arkansas State University (USA). His academic career includes roles as Research Assistant (2014-2015), Associate Professor (2018-2024), and current Professorship. He has served as the Head of the Molecular Biology and Genetics Department and Deputy Department Chair. Educational Background: Bachelor's in Biology (2005) – Hatay Mustafa Kemal University Master's in Biochemistry (2008) – Hatay Mustafa Kemal University PhD in Molecular Biology (2014) – Arkansas State University Research Interests: His work focuses on molecular mechanisms of bacterial pathogenesis, antibiotic resistance, and food safety. Key areas include: Genomic characterization of multi-drug resistant pathogens like E. coli and Salmonella Development of rapid diagnostic tools for foodborne pathogens Investigation of prion protein roles in Brucella infections Antibacterial properties of natural compounds Collagen biochemistry in aquatic species Publications and Awards: He has published 30+ peer-reviewed articles, 5 book chapters, and received awards such as: Finalist in Young Scientist Award (Best Developing Young Scientists) International Association for Food Protection (IAFP) prizes TUBITAK Publication Incentive Awards American scholarships (Arkansas State University) Professional Contributions: Serves as a reviewer for journals like Free Radical Biology and Medicine , editor for Adıyaman University Journal of Science , and member of organizations like the Turkish Microbiology Society. He has conducted research projects on antibiotic resistance in environmental and food samples, and led studies on collagen biochemistry in endemic fish species. Labs and Collaborations: Leads the Molecular Biology and Genetics Laboratory at Adiyaman University, collaborating with institutions like Arkansas State University and Instituto Politécnico do Porto.
- Quantitative Finance
- Decision Theory
- Risk Theory
- +۷ مورد دیگر
Francesca Beccacece is an Associate Professor of Financial Mathematics at Bocconi University in Milan. She has held leadership roles as Director of the Bachelor of Science in Economics and Management for Arts, Culture, and Communication (2016–2019) and Director of the Master in Quantitative Finance and Risk Management (2008–2010; 2012–2014). Her educational background includes a Degree in Economics from Università di Parma. Her research focuses on Quantitative Finance (financial markets models, asset pricing, term structure models), Decision Theory (benchmarking models in finance), and Risk Theory (default risk modeling). Recent work explores multivariate risk attitudes in sustainability policies and regulatory principles for financial amortization. Earlier studies include applications of functional ANOVA in utility theory and stochastic frameworks for project evaluation. Teaching responsibilities span undergraduate and graduate courses, including Financial Models for Valuation , Mathematics , and Quantitative Methods for Social Sciences . Past courses include Mathematics, Advanced Financial Mathematics, Quantitative Methods for Management, and Fixed Income/Asset Pricing in master programs. Her contributions to academia include curriculum development and editorial work in finance-related journals. She advises on financial modeling and risk strategies, though specific advisees are not listed. No scientific awards were explicitly mentioned in the provided text.
Jing Duمشاهده پروفایل
عضو هیئت علمی
Jing Du, MD, PhD, is an Instructor of Medicine in Medical Oncology at Yale School of Medicine. She specializes in treating breast cancer patients at Smilow Cancer Hospital and focuses on tumor microenvironment research, using spatial multi-omics techniques to identify novel biomarkers and therapies. Dr. Du earned her MD from Shanghai Jiao Tong University School of Medicine and her PhD in Biochemistry from the University of South Carolina. She completed residency at Yale New Haven Health and a fellowship in Medical Oncology-Hematology at Yale School of Medicine. Education: MD: Shanghai Jiao Tong University School of Medicine PhD in Biochemistry: University of South Carolina Research Interests: Dr. Du’s work centers on the tumor microenvironment and its role in cancer progression. She investigates biomarkers using advanced spatial multi-omics and collaborates on translational studies to bridge lab discoveries with clinical applications. Her research aims to reduce treatment toxicities and improve patient outcomes in breast cancer. Publications: Her work spans tumor immunology, platelet biology, and diabetes-related mechanisms. Key topics include TLT-1’s role in suppressing CD8+ T cells, unfolded protein response in platelets, and mitophagy’s protective effects in diabetic platelets. Awards: Browning Award for professionalism and dedication during residency. Clinical Trials: Leads investigator-initiated trials evaluating new breast cancer therapies, including roles in studies of elacestrant, camizestrant, and datopotamab deruxtecan.
Brinda Emuمشاهده پروفایل
دانشیار
- HIV/AIDS
- Oncology
- Immunology
- +۵ مورد دیگر
Brinda Emu, MD, is an Associate Professor of Medicine (Infectious Diseases) at Yale School of Medicine, with secondary appointments in Pathology. She leads the Cancer-ID Clinic and co-leads the Cancer Microbiology Working Group at Yale Cancer Center. Her research focuses on HIV-associated malignancies, examining how chronic viral infections weaken immune defenses and promote tumor development. Dr. Emu received her BA from Harvard University, MD from Johns Hopkins, completed residency at Beth Israel Deaconess Medical Center, and infectious diseases fellowship at UCSF. She previously worked at Genentech developing novel therapies for infectious diseases and oncology. Her research interests include immune correlates of protection in HIV, T-cell dysfunction in cancer, and HIV-associated immune dysregulation. Key collaborations involve Kurt Schalper, Amy Justice, Geliang Gan, and Albert C. Shaw. Notable studies include analyses of HIV's impact on head and neck cancer survival, T-cell exhaustion in cancer patients, and CD36 receptor roles in tumor immunology. Dr. Emu has published extensively on HIV-cancer intersections, immune checkpoint inhibitors in HIV-positive patients, and SARS-CoV-2 vaccination strategies for immunocompromised individuals. Her work appears in Clinical Infectious Diseases , Immunity , and Nature . She leads clinical trials on HIV latency mechanisms and chairs initiatives promoting diversity in infectious diseases education.
Min-Jong Kangمشاهده پروفایل
دانشیار
Min-Jong Kang is an Associate Professor of Medicine in the Department of Pulmonary, Critical Care & Sleep Medicine at Yale School of Medicine. He holds appointments in the CPIRT Center for Pulmonary Injury, Inflammation, Repair and Therapeutics. His research focuses on mitochondrial dysfunction and innate immunity in aging-related lung diseases like COPD and IPF, with a particular interest in the MAVS protein's role in host resilience. He earned his MD from Seoul National University (1991), PhD (2002) and MPH (1999) from the same institution. Research Interests: Dr. Kang investigates how mitochondrial biology intersects with aging and immune dysregulation. His work explores mechanisms linking mitochondrial antiviral signaling proteins (MAVS) to chronic lung diseases, including how cellular senescence and mitochondrial dysfunction drive disease progression. Current projects include studying MIF-CD74 signaling in pulmonary fibrosis and mitochondrial non-coding RNAs' protective roles against cigarette smoke injury. Laboratory: The Kang Lab focuses on translational research to identify novel therapeutic targets for COPD and IPF. Recent work highlights the potential of targeting VISTA immune regulators and mitochondrial retrograde signaling pathways. Dr. Kang collaborates with leading researchers like Naftali Kaminski and Maor Sauler on multi-disciplinary studies. Future Directions: His team aims to bridge aging biology with pulmonary medicine, developing interventions that improve mitochondrial health to combat age-related lung pathologies. Ongoing studies explore senescence markers and mitochondrial quality control mechanisms in lung aging.
Hongil Kimمشاهده پروفایل
پژوهشگر ارشد
- Infectious Diseases
- Vaccine Development
- Immunology
- +۳ مورد دیگر
Hongil Kim is a Research Fellow in the Department of Internal Medicine at the Yale School of Medicine, Yale University. His research focuses on infectious diseases, particularly the pathogenesis of bacterial pathogens like Orientia tsutsugamushi (causative agent of scrub typhus) and viral infections such as HIV and severe fever with thrombocytopenia syndrome virus (SFTSV). He explores vaccine development strategies, host-pathogen interactions, and immunological mechanisms governing protective immunity. Key research interests include understanding bacterial adhesion and invasion mechanisms (e.g., ScaA and ScaB proteins), cytokine regulation in immune responses, and the design of cross-protective subunit vaccines. His work integrates molecular biology, immunology, and epidemiology to address global health challenges. Kim’s publications highlight advancements in recombinant antigen-based vaccines, nanoparticle-enhanced immunization, and the role of cytokines like IL-10 and type I interferons in suppressing antiviral immunity. He also investigates pulmonary inflammation and vascular dysregulation during severe bacterial infections, contributing to our understanding of disease pathophysiology. Despite his prolific output, no scientific awards or grants are explicitly mentioned in the provided text. His research has implications for developing diagnostic tools, therapeutic strategies, and preventive measures against emerging and re-emerging infectious diseases.
Asawari Kordeمشاهده پروفایل
پژوهشگر
Asawari Korde is an Associate Research Scientist at the Yale School of Medicine's Department of Pulmonary, Critical Care & Sleep Medicine. Her research focuses on microRNA regulation in lung biology, immune responses, and respiratory diseases. She investigates mechanisms such as EGF receptor signaling in lung injury, miRNA roles in cancer and inflammation, and host defense against viral/bacterial infections. Collaborations include work on antiviral immunity with neomycin and tumor progression suppression via TLT-1. Her findings bridge molecular pathways (e.g., lysosomal dysfunction in SARS-CoV-2 infections) to clinical implications in asthma, chronic rhinosinusitis, and oncology. Key Areas: Lung injury, miRNA regulation, immune modulation, respiratory infections Techniques: Animal models, molecular biology, immunohistochemistry Recent work highlights miR-1's protective role in endothelial integrity and its therapeutic potential in acute lung injury. Her studies on platelet-derived factors and viral immunity underscore translational applications in infectious diseases.
Lei Pengمشاهده پروفایل
پژوهشگر
Lei Peng is an Associate Research Scientist in the Department of Genetics at Yale University School of Medicine. Their research focuses on advancing cancer immunotherapy, particularly through CRISPR-based genetic screens and engineering of immune cells like CAR-NK and CAR-T cells. Peng has contributed to breakthroughs in viral vaccine development, including Omicron-specific mRNA vaccines and monoclonal antibody generation. Their work integrates cutting-edge gene editing technologies with immunological insights to address challenges in cancer treatment and infectious diseases. Key collaborations include projects with Paul Renauer and Sidi Chen, targeting genetic checkpoints in NK cells and SARS-CoV-2 variant-specific immunity. Research interests span molecular virology, gene delivery systems (AAV/Sleeping Beauty), and structural biology of antibodies. Peng's studies often bridge basic science with translational applications, aiming to enhance therapeutic efficacy through systems-level approaches. Publications highlight innovations in CRISPR screens for cancer resistance mechanisms, cryo-EM structural analysis of antiviral antibodies, and multiplexed mRNA vaccine strategies. While no awards are explicitly listed, their contributions to high-impact journals like Nature Biotechnology reflect significant scholarly recognition.
- Autoimmune Diseases
- Immunology
- Diabetes Research
- +۳ مورد دیگر
Kevan Herold, MD, is the C.N.H. Long Professor of Immunobiology and Medicine at Yale School of Medicine. His dual appointments in Immunobiology and Endocrinology reflect his translational research focus on autoimmune diabetes mechanisms and therapies. He leads clinical trials evaluating teplizumab, a monoclonal antibody that delays Type 1 diabetes onset, and chairs NIDDK's TrialNet network. His lab investigates beta cell protection, checkpoint inhibitor-induced diabetes, and immune regulation in autoimmune diseases. Education : Jefferson Medical College (MD 1979), Pennsylvania State University (BS 1977). Fellowship at University of Chicago (1984). Research : Translational immunology targeting Type 1 diabetes pathogenesis. Key areas include: immune checkpoint therapy effects, beta cell preservation, and genetic risk factors. Recent work explores teplizumab's long-term immune modulation and diabetes reversal via reprogrammed cells. Clinical Focus : Managing Type 1/2 diabetes, post-cancer therapy autoimmune diabetes, and hypoglycemia. Leads PROTECT trial preserving beta cell function in newly diagnosed patients. Awards : Not explicitly listed but recognized for teplizumab clinical trial milestones and TrialNet leadership. Lab & Teams : Herold Lab focuses on immunotherapy development. Collaborates with Ana Perdigoto (Yale Internal Medicine) and Paula Preston-Hurlburt (Yale Immunobiology). Active in Yale's Human and Translational Immunology Program and Cancer Immunology initiatives.
Ying Chenمشاهده پروفایل
پژوهشگر
Dr. Ying Chen is a Research Scientist and Lecturer in Environmental Health Sciences at the Yale School of Public Health. She holds a MD from Xiangya School of Medicine and a PhD in Environmental and Public Health Sciences. Her work focuses on redox homeostasis and antioxidant deficiencies in diseases linked to environmental and dietary exposures. Key research areas include alcohol-associated liver disease, 1,4-dioxane-induced liver cancer mechanisms, and antioxidant interactions in the nervous system. Dr. Chen’s research employs transgenic mouse models, multi-omics analysis, and histopathology to study oxidative stress in disease contexts. She collaborates with institutions like the Yale Superfund Research Center and the Vasiliou Lab. Notable projects include investigating CYP2E1’s role in 1,4-dioxane toxicity and glutathione’s protective mechanisms in liver lipid metabolism. Her publications span Nature Communications , Cell Metabolism , and Archives of Toxicology , addressing topics like AI-driven patient triage systems and epigenomic signatures of oxidative stress. She serves on committees for the Stolwijk Fellowship and actively reviews for peer journals. Dr. Chen’s lab is located at 60 College Street, New Haven, CT. Her research aims to bridge mechanistic insights with public health applications, particularly in environmental carcinogen risk assessment and disease prevention strategies.
Terho Lehtimäki is a Professor and Head of the Department of Clinical Chemistry at Tampere University's Faculty of Medicine and Health Technology. He also serves as Chief Physician at Fimlab Laboratories, a major clinical laboratory in Finland. His academic roles include being a docent in medical biochemistry and clinical chemistry, and he holds an eMBA degree. His research focuses on cardiovascular disease biomarkers, atherosclerosis, omics technologies, and genetic/epigenetic factors influencing complex traits. He leads major studies like the Tampere Vascular Study and contributes to over 35 international consortia. With 1200+ peer-reviewed publications and an H-index of 147, his work has driven discoveries in over 5000 genetic variants. Notable recognitions include membership in Academia Europaea and the University of Tampere Science Prize. Education & Career MD/PhD (1992) Docent in Medical Biochemistry (1996, University of Tampere) Docent in Clinical Chemistry (2003, University of Eastern Finland) eMBA (2013) Research Interests Cardiovascular biomarkers for risk prediction Omics-based systems biology approaches Functional genetics of complex traits Epigenetic inheritance mechanisms Multimodal cohort studies (e.g., Young Finns Study) Publications & Impact His work spans Nature, Science, and NEJM, with key contributions to understanding atherosclerosis biology, genetic risk factors, and clinical translation of omics data. Recent trends emphasize multi-omics integration and precision medicine applications. Awards & Leadership Over €15M in grant funding 3 spin-off companies Scientific leadership roles in >35 international initiatives Reviewer for 50+ journals and 15 funding agencies Teaching & Mentorship Trained over 60 PhD/MSc students, many now leading academic and clinical roles. Active in problem-based learning methodologies at Tampere University's Center of Excellence. Labs & Teams Directs the Clinical Chemistry Department's research group, collaborating closely with Fimlab Laboratories and international networks like the European Eye Consortium.
- Viral Immunology
- Vaccination
- Immunological Ageing
- +۳ مورد دیگر
Marieke van der Heiden is a Post-doctoral Researcher in Viral Immunology and Vaccination at the University of Groningen's Faculty of Medical Sciences, affiliated with the Translational Immunology Groningen (TRIGR) group. Her research focuses on vaccine responses, immunological aging, and biomarkers in vaccination, particularly in immunocompromised populations such as cancer patients, kidney transplant recipients, and the elderly. She has contributed to studies on SARS-CoV-2 vaccination efficacy, T cell responses in solid tumors, and the impact of age and comorbidities on vaccine outcomes. Her expertise spans viral immunology, T-cell biology, and translational research. Notable projects include the RECOVAC trial assessing vaccine responses in kidney transplant patients and investigations into inflammageing markers linked to frailty. Collaborations involve multidisciplinary teams addressing immune responses in chronic diseases and infectious threats. Publications highlight her work on vaccine efficacy, T-cell functionality, and immune profiling in clinical populations. Grants and collaborations are evident through her involvement in randomized controlled trials and epidemiological studies. She leads or co-leads research projects on vaccine immunogenicity and immune correlates of protection, contributing to global efforts in infectious disease prevention.
Tobias E. Hectorمشاهده پروفایل
پژوهشگر ارشد
Dr. Tobias E. Hector is a Postdoctoral Researcher in the Department of Biology at the University of Oxford, working within the King Lab. His research examines the critical intersection of thermal biology, host-parasite interactions, and climate change, focusing on how rising temperatures reshape infectious disease dynamics and host thermal performance across ecological and evolutionary timescales. His primary research investigates how parasite exposure drives shifts in host thermal tolerance and the cascading consequences for host and parasite responses to environmental warming. Key interests include eco-evolutionary feedback loops in disease systems, thermal acclimation effects on host immunity, and the molecular mechanisms underlying pathogen virulence under temperature stress. This work integrates experimental ecology with evolutionary theory to predict disease outbreak risks in rapidly changing climates. Analysis of Dr. Hector's 15 recent publications (2019-2025) reveals a cohesive research trajectory centered on temperature-pathogen-host interdependencies. Dominant themes include warming-induced excess mortality in infected ectotherms, thermal acclimation as a protective mechanism against pathogens, and pathogen molecular evolution driven by within-host competition. His studies span thermal physiology, disease ecology, and evolutionary biology, consistently highlighting climate change as a catalyst for altered host-pathogen dynamics. Dr. Hector is embedded in the King Lab at the University of Oxford, a research group specializing in experimental investigations of climate-disease interactions. The lab employs controlled thermal environments and multi-host pathogen systems to dissect mechanisms linking environmental change to infectious disease outcomes, with strong emphasis on physiological and evolutionary processes.